Heparin inhibits lipopolysaccharide (LPS) binding to leukocytes and LPS-induced cytokine production

Journal of Biomedical Materials Research - Part A

Volumn 66, Issue 2, 2003, Pages 376-384

  Anastase Ravion, Sylvie ^a   Blondin, Catherine ^a   Cholley, Béatrice ^b   Haeffner Cavaillon, Nicole ^b   Castellot, John J ^c   Letourneur, Didier ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b HÔPITAL BROUSSAIS   (France)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD14; Cytokines; Glycosaminoglycan; Human blood monocytes; Inflammation

Indexed keywords

BLOOD; CELLS; ESCHERICHIA COLI; GENES; POLYSACCHARIDES; PROTEINS;

INFLAMMATORY RESPONSE;

BIOMATERIALS;

BACTERIUM LIPOPOLYSACCHARIDE; BIOMATERIAL; CD14 ANTIGEN; CYTOKINE; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN DERIVATIVE; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD14 GENE; CELL ACTIVATION; CHO CELL; CYTOKINE PRODUCTION; FLOW CYTOMETRY; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE; MATERIAL COATING; MONOCYTE; NONHUMAN;

EID: 0344738674     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.a.10604     Document Type: Article

References (44)

1. Abraham SN, Malaviya R. Mast cells in infection and immunity. Infect Immun 1997;65:3501-3508.
2. Galli SJ, Wershill BK. The two faces of the mast cells. Nature 1996;381:21-22.
3. Blondin C, Bataille I, Letourneur D. Polysaccharides for vascular cell targeting. Crit Rev Ther Drug Carrier Syst 2000;17:327-375.
4. Letourneur D, Caleb BL, Castellot JJ. Heparin binding, internalisation and metabolism in vascular smooth muscle cells. I. Upregulation of heparin binding correlates with antiproliferative activity. J Cell Physiol 1995;165:676-686.
5. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;82:3253-3258.
6. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-148.
7. Ramsden L, Rider CC. Selective and differential binding of interleukin (IL)-1α, IL-1β, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 1992;22:3027-3031.
8. Goger B, Halden Y, Rek A, Mosl R, Pye D, Gallagher J, Kungl AJ. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites. Biochemistry 2002;41:1640-1646.
9. Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, Cohen IR, Naparstek Y. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 1990;20:493-499.
10. Frieri M, Metcalfe DD. Analysis of the effect of mast cells granules on lymphocyte blastogenesis in the absence or the presence of mitogens: Identification of heparin as a granule-associated suppressor factor. J Immunol 1983;131:1942-1947.
11. Dziarski R. Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J Immunol 1989;143:356-365.
12. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002;110:127-136.
13. Attanasio M, Gori AM, Giusti B, Pepe G, Comeglio P, Brunetti T, Prisco D, Abbate R, Gensini GF, Neri Serneri GG. Cytokine gene expression in human LPS- and IFNγ stimulated mononuclear cells is inhibited by heparin. Thromb Haemost 1998;79:959-962.
14. Myrvang Hogasen K, Abrahamsen TG. Heparin suppresses lipopolysaccharide-induced monocyte production of several cytokines, but simultaneously stimulates C3 production. Thromb Res 1995;80:179-184.
15. Heinzelmann M, Miller M, Platz A, Gordon LE, Herzig DO, Polk HC. Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes. Ann Surg 1999;229:542-550.
16. Cavaillon JM, Marie C, Caroff M, Ledur A, Godard I, Poulain D, Fitting C, Haeffner-Cavaillon N. CD14/LPS receptor exhibits lectin-like properties. J Endotoxin Res 1996;3:471-480.
17. Barstad RM, Ovrum E, Ringdal MA, Oystese R, Hamers MJ, Veiby OP, Rolfsen T, Stephens RW, Sakariassen KS. Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br J Haematol 1996;94:517-525.
18. Johnell M, Elgue G, Larsson R, Larsson A, Thelin S, Siegbahn A. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg 2002;124:321-332.
19. Lundgren B, Holst A, Tarnholm A, Rolfsen W. Cellular reaction following cataract surgery with implantation of the heparin-surface-modified intraocular lens in rabbits with experimental uveitis. J Cataract Refract Surg 1992;18:602-606.
20. Hildebrandt P, Sayyad M, Rzany A, Schaldach M, Seiter H. Prevention of surface encrustation of urological implants by coating with inhibitors. Biomaterials 2001;22:503-507.
21. Bouma M, Maessen J, Weerwind P, Dentener M, Fransen E, de Jong D, Buurman W. Release of lipopolysaccharide toxicitymodulating proteins in patients undergoing cardiopulmonary bypass using noncoated and heparin-coated extracorporeal circuits: A clinical pilot study. Chest 1997;111:577-583.
22. Butler J, Murithi EW, Pathi VL, MacArthur KJ, Berg GA. Durollo II heparin bonding does not attenuate cytokine release or improve pulmonary function. Ann Thorac Surg 2002;74:139-142.
23. Stearns NA, Prigent-Richard S, Letourneur D, Castellot JJ. Synthesis and characterization of highly sensitive heparin probes for detection of heparin-binding proteins. Anal Biochem 1997;247:348-356.
24. Blondin C, Le Dur A, Cholley B, Caroff M, Haeffner-Cavaillon N. Lipopolysaccharide complexed with soluble CD14 binds to normal human monocytes. Eur J Immunol 1997;27:3303-3309.
25. Cavaillon JM, Duff G. Cytokines and the cellular mechanism of inflammation. In: Theze J, editor. The cytokine network and immune functions. New York: Oxford University Press; 1999. p 251-261.
26. Haeffner-Cavaillon N, Cavaillon JM, Moreau M, Szabo L. Interleukin 1 secretion by human monocytes stimulated by the isolated polysaccharide region of the Bordetella pertussis endotoxin. Mol Immunol 1984;21:389-395.
27. Solberg R, Schoz T, Videm V, Okkerthaug C, Aasen AO. Heparin coating reduces cell activation and mediator release in an in vitro venovenous bypass model for liver transplantation. Transpl Int 1998;11:252-258.
28. Jahr TG, Sundan A, Lichenstein HS, Espevik T. Influence of CD14, LBP and BPI in the monocyte response to LPS of different polysaccharide chain length. Scand J Immunol 1995;42:119-127.
29. Matsuno R, Aramaki Y, Arima H, Adachi Y, Ohno N, Yadomae T, Tsuchiya S. Contribution of CR3 to nitric oxide production from macrophages stimulated with high-dose of LPS. Biochem Biophys Res Commun 1998;244:115-119.
30. Pugin J, Heumann D, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. CD14 is a pattern recognition receptor. Immunity 1994;1:509-516.
31. Dziarski R, Tapping R, Tobias PS. Binding of bacterial peptidoglycan to CD14. J Biol Chem 1998;273:8680-8690.
32. Cleveland MG, Gorham JD, Murphy TL, Tuomanen E, Murphy KM. Lipoteichoic acid preparations from gram-positive bacteria induced interleukin-12 through a CD14-dependent pathway. Infect Immun 1996;64:1906-1912.
33. Espevik T, Otterlei M, Skjak-Braek G, Ryan L, Wright SD, Sundan A. The involvement of CD14 in stimulation of cytokine production by uronic acid polymers. Eur J Immunol 1993;23:255-261.
34. Heinzelmann M, Polk HC, Miller FN. Modulation of lipopolysaccharide-induced monocyte activation by heparin-binding protein and fucoidan. Infect Immun 1998;66:5842-5847.
35. Dziarski R, Gupta D. Heparin, sulfated heparinoids and lipoteichoic acids bind to the 70-kDa peptidoglyan/lipopolysaccharide receptor protein on lymphocytes. J Biol Chem 1994;269:2100-2110.
36. Dziarski R. Cell-bound albumin is the 70-kDa peptidoglycan-, lipopolysaccharide-, and lipoteichoic acid-binding protein on lymphocytes and macrophages. J Biol Chem 1994;269:20431-20436.
37. Bradbury MG, Parish CR. Characterization of lymphocyte receptors for glycosaminoglycans. Immunology 1991;72:231-238.
38. Dawes J. Interactions of heparin in the vascular environment. Haemostasis 1993;23:212-219.
39. Leculier C, Benzerara O, Couprie N, Francina A, Lasne Y, Archimbaud E, Here D. Specific binding between human neutrophils and heparin. Br J Haematol 1992;81:81-85.
40. Matzner Y, Marx G, Drexler R, Eldor A. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984;52:134-137.
41. Abbate R, Gori AM, Modesti PA, Attanasio M, Martini F, Colella A, Giusti B, Cecioni I, Neri Semeri GG. Heparin, monocytes, and procoagulant activity. Haemostasis 1990;20:98-100.
42. Leung L, Saigo K, Grant D. Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes: Effect of histidine-rich glycoprotein. Blood 1989;73:177-184.
43. Monick MM, Powers L, Butler N, Yarovinsky T, Hunninghake GW. Interaction of matrix with integrin receptors is required for optimal LPS-induced MAP kinase activation. Am J Physiol Lung Cell Mol Physiol 2002;283:390-402.
44. Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002;23:301-304.